Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Refractory hypertension: definition, prevalence, and patient characteristics.

Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, Cofield SS, Oparil S, Calhoun DA.

J Clin Hypertens (Greenwich). 2012 Jan;14(1):7-12. doi: 10.1111/j.1751-7176.2011.00556.x. Epub 2011 Nov 15.

2.

Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?

Mahmud A, Mahgoub M, Hall M, Feely J.

Am J Hypertens. 2005 Dec;18(12 Pt 1):1631-5.

PMID:
16364838
3.

[Prevalence of true resistant hypertension among uncontrolled hypertensive patients referred to a tertiary health care center].

Henine N, Kichou B, Kichou L, Benbouabdellah M, Boubchir MA, Madiou A, Hammouche A, Saheb B.

Ann Cardiol Angeiol (Paris). 2016 Jun;65(3):191-6. doi: 10.1016/j.ancard.2016.04.003. Epub 2016 May 12. French.

PMID:
27180567
4.

High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension.

de Haro Moraes C, Figueiredo VN, de Faria AP, Barbaro NR, Sabbatini AR, Quinaglia T, Ferreira-Melo SE, Martins LC, Demacq C, Júnior HM.

J Hum Hypertens. 2013 Apr;27(4):225-30. doi: 10.1038/jhh.2012.29. Epub 2012 Jul 19.

PMID:
22810172
5.
6.

Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.

Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA.

J Hypertens. 2016 May;34(5):1005-10. doi: 10.1097/HJH.0000000000000870.

PMID:
26886564
7.

The role of spironolactone in the treatment of patients with refractory hypertension.

Ouzan J, Pérault C, Lincoff AM, Carré E, Mertes M.

Am J Hypertens. 2002 Apr;15(4 Pt 1):333-9.

PMID:
11991219
8.

Resistant or refractory hypertension: are they different?

Modolo R, de Faria AP, Almeida A, Moreno H.

Curr Hypertens Rep. 2014 Oct;16(10):485. doi: 10.1007/s11906-014-0485-1. Review.

PMID:
25139782
9.

Prevalence, treatment, and control of hypertension in residents of skilled nursing facilities.

Coover KL, Ryan-Haddad A, Faulkner MA, Hilleman DE.

Consult Pharm. 2008 Apr;23(4):317-23.

PMID:
18454588
10.

An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.

Miranda RD, Mion D Jr, Rocha JC, Kohlmann O Jr, Gomes MA, Saraiva JF, Amodeo C, Filho BL.

Clin Ther. 2008 Sep;30(9):1618-28. doi: 10.1016/j.clinthera.2008.09.008.

PMID:
18840367
11.

Resistant hypertension and aldosterone: an update.

Clark D 3rd, Ahmed MI, Calhoun DA.

Can J Cardiol. 2012 May;28(3):318-25. doi: 10.1016/j.cjca.2012.03.010. Epub 2012 Apr 21. Review.

PMID:
22521297
12.

Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority trial.

Hong SJ, Ahn TH, Baek SH, Cho WH, Jeon HK, Kwan J, Yoon MH, Lee KJ, Lim DS.

Clin Ther. 2006 Apr;28(4):537-51. Erratum in: Clin Ther. 2006 Aug;28(8):1245. Jeon, Hyee-Kyoung [corrected to Jeon, Hui-Kyung]; Kyun, Jun [corrected to Kwan, Jun].

PMID:
16750465
13.

Hypertension management in chronic kidney disease: translating guidelines into daily practice.

De Nicola L, Borrelli S, Chiodini P, Zamboli P, Iodice C, Gabbai FB, Conte G, Minutolo R.

J Nephrol. 2011 Nov-Dec;24(6):733-41. doi: 10.5301/JN.2011.6335.

PMID:
21319133
14.

Dilated cardiomyopathy with hypertension: prevalence and response to high-dose β1-adrenoceptor antagonist therapy.

Zheng X, Chen S, Wang J, Yang T, Chen Y.

Clin Exp Pharmacol Physiol. 2009 Sep;36(9):945-9. doi: 10.1111/j.1440-1681.2009.05184.x. Epub 2009 Mar 26.

PMID:
19473337
15.
16.
17.

[Antihypertensive therapy for refractory morning hypertension in patients on peritoneal dialysis].

Kuriyama S, Otsuka Y, Iida R, Kobayashi S, Yamagishi H, Hosoya T.

Nihon Jinzo Gakkai Shi. 2005;47(1):38-45. Japanese.

PMID:
15754762
18.

Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.

Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB.

J Am Soc Hypertens. 2012 Sep-Oct;6(5):338-45. doi: 10.1016/j.jash.2012.07.003.

PMID:
22995802
19.

Resistant hypertension and hyperaldosteronism.

Gonzaga CC, Calhoun DA.

Curr Hypertens Rep. 2008 Dec;10(6):496-503. Review.

PMID:
18959838
20.

Isradipine in the treatment of hypertension. Some additional effects observed during a one-year study.

Mayer O, Polivkova H, Rottenborn J.

Am J Hypertens. 1991 Feb;4(2 Pt 2):140S-143S.

PMID:
1827005

Supplemental Content

Support Center